ClinicalTrials.gov record
Terminated Phase 1 Interventional

A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74

ClinicalTrials.gov ID: NCT06597656

Public ClinicalTrials.gov record NCT06597656. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of Delandistrogene Moxeparvovec Following Plasmapheresis in Subjects With Duchenne Muscular Dystrophy and Pre-existing Antibodies to AAVrh74

Study identification

NCT ID
NCT06597656
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Enrollment
3 participants

Conditions and interventions

Interventions

  • Plasmapheresis Procedure
  • delandistrogene moxeparvovec Genetic

Procedure · Genetic

Eligibility (public fields only)

Age range
4 Years to 8 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 17, 2024
Primary completion
Aug 4, 2025
Completion
Aug 4, 2025
Last update posted
Sep 3, 2025

2024 – 2025

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Florida, College of Medicine Gainesville Florida 32610
Washington University School of Medicine in St. Louis St Louis Missouri 63110
Nationwide Children's Hospital Columbus Ohio 43205

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06597656, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2025 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06597656 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →